Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teligent Targets Smaller Customers As It Seeks Sustainable Margins

Executive Summary

You may also be interested in...



Ophthalmics Are Next Frontier For Teligent

US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.

Teligent Weighs Sales Of Non-Core Assets

US topicals, ophthalmics and injectables generics player Teligent has asked an investment bank to help it explore selling off non-core assets. The New Jersey-based firm wants funds to help capitalize on its newly built injectables facility.

Teligent Has No Explanation For Sudden Share-Price Slide

US niche generics specialist Teligent is at a loss to explain why its share price has tumbled in recent times as it ramps up production at an expanded injectables facility.

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel